| Literature DB >> 29664957 |
Linghang Wang1,2,3, Yonghong Zhang3,4, Keyi Xu1, Tao Dong2,3, Sarah Rowland-Jones2, Louis-Marie Yindom2.
Abstract
BACKGROUND: The HIV pandemic remains the most serious challenge to public health worldwide. The hallmark characteristics of the disease is the eventual failure of the immune system to control opportunistic infections and death. However not everyone who has HIV develops the disease at the same rate and so we are studying how the immune system works to control the virus in those who have been infected for decades and remain relatively healthy without the need of anti-retroviral therapy (ART).Entities:
Mesh:
Substances:
Year: 2018 PMID: 29664957 PMCID: PMC5903672 DOI: 10.1371/journal.pone.0195452
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of surviving HIV-1 infected individuals at enrolment.
| Gender | Total number (n = 258) | Mean±SD (%) |
|---|---|---|
| Male | 113 | 43.80% |
| Female | 145 | 56.20% |
| Age (years) | 258 | 42.98 ± 9.84 (27–60) |
| Duration of Infection (years) | 258 | 14.56 ± 1.42 (12–16) |
| Route of infection / therapy | Total number (n = 258) | % |
| Plasma donation | 258 | 100% |
| Other | 0 | 0 |
| ART before 2004 | 0 | 100% |
| ART after 2004 | 121 | 46.90% |
| Viral load | Total number | % |
| VL < 50 | 27 | 29.03% |
| VL ≤ 2000 (≤3.3log) | 8 | 8.60% |
| VL > 2000 (>3.3log) | 58 | 62.37% |
| CD4 ≥ 500 | 81 | 34.03% |
| 200 ≥ CD4 < 500 | 87 | 36.56% |
| CD4 < 200 | 70 | 29.41% |
*: Viral loads were measured and reported as copies per mL of blood collected from 93 participants
†: CD4+ T cell counts were performed and reported as number of CD4+ T cells per mL of blood, 238 participants had baseline CD4 data.
KIR frequency distribution between SM patients and healthy controls.
| KIR gene | SM patients % | Healthy control % | P |
|---|---|---|---|
| n = 261 | n = 252 | ||
| 98.5 | 100 | 0.124 F | |
| 22.6 | 21.8 | 0.915 | |
| 95.8 | 99.2 | ||
| 99.2 | 100 | 0.499 F | |
| 39.5 | 42.9 | 0.435 | |
| 34.9 | 37.3 | 0.566 | |
| 21.5 | 20.6 | 0.820 | |
| 13.8 | 17.9 | 0.207 | |
| 98.1 | 97.2 | 0.571 F | |
| 28.7 | 29.4 | 0.875 | |
| 97.3 | 94.1 | 0.068 | |
| 100 | 100 | - | |
| 100 | 100 | - | |
| 31 | 38.1 | 0.096 | |
| 98.5 | 100 | 0.124 F |
Pearson Chi-Square was used to perform the comparison.
*: Fisher’s Exact Test. P<0.05 was significant.
–represents no comparison.
HLA class I frequencies between cases and controls.
| HLA class I | SM patients(n = 233) % | Healthy controls(n = 252) % | P |
|---|---|---|---|
| HLA-A alleles | |||
| A*01 | 10.3 | 6.8 | 0.164 |
| A*02 | 53.2 | 47.8 | 0.235 |
| A*03 | 8.2 | 6.8 | 0.563 |
| A*11 | 24.5 | 26.3 | 0.644 |
| A*24 | 24.5 | 29.9 | 0.182 |
| A*26 | 2.6 | 6.4 | |
| A*31 | 5.6 | 6.4 | 0.713 |
| A*32 | 6.4 | 4.8 | 0.428 |
| A*33 | 21.0 | 24.7 | 0.338 |
| HLA-B alleles | |||
| B*07 | 7.7 | 9.2 | 0.571 |
| B*08 | 2.6 | 2.0 | 0.668 |
| B*13 | 21.0 | 26.3 | 0.174 |
| B*15 | 17.6 | 20.3 | 0.446 |
| B*27 | 7.3 | 4.0 | 0.113 |
| B*35 | 6.9 | 5.6 | 0.557 |
| B*37 | 3.9 | 2.8 | 0.510 |
| B*38 | 5.6 | 6.8 | 0.587 |
| B*39 | 3.9 | 4.0 | 0.945 |
| B*40 | 29.2 | 25.5 | 0.363 |
| B*44 | 13.7 | 17.5 | 0.252 |
| B*46 | 9.4 | 10.0 | 0.848 |
| B*48 | 5.6 | 4.4 | 0.545 |
| B*51 | 14.2 | 16.7 | 0.436 |
| B*52 | 8.2 | 7.2 | 0.685 |
| B*54 | 6.4 | 5.2 | 0.554 |
| B*55 | 2.2 | 3.6 | 0.346 |
| B*57 | 4.7 | 3.2 | 0.386 |
| B*58 | 11.6 | 11.6 | 0.991 |
| HLA-C alleles | |||
| Cw*01 | 18.6 | 18.3 | 0.942 |
| Cw*02 | 5.8 | 2.0 | |
| Cw*03 | 33.6 | 39 | 0.22 |
| Cw*04 | 9.7 | 10.8 | 0.714 |
| Cw*06 | 29.7 | 27.9 | 0.672 |
| Cw*07 | 28.8 | 29.1 | 0.938 |
| Cw*08 | 22.6 | 16.3 | 0.085 |
| Cw*12 | 11.1 | 9.2 | 0.492 |
| Cw*14 | 10.6 | 13.9 | 0.271 |
| Cw*15 | 11.1 | 13.9 | 0.344 |
Centromeric and telomeric motif and genotype distribution in the study population.
| SM patients (%) | Healthy controls (%) | P | |
|---|---|---|---|
| cen-A | 72.8 | 75.8 | 0.438 |
| cen-B1 | 6.5 | 3.6 | 0.129 |
| cen-B2 | 14.2 | 16.7 | 0.435 |
| cen-B3 | 23 | 23.4 | 0.909 |
| cen-Bx | 6.1 | 4.4 | 0.371 |
| tel-A | 96.9 | 94.1 | 0.115 |
| tel-B1 | 25.3 | 32.9 | 0.570 |
| tel-Bx | 16.1 | 12.7 | 0.275 |
| c-A/A | 52.5 | 52.4 | 0.980 |
| c-A/B1 | 4.6 | 3.6 | 0.558 |
| c-A/B2 | 13 | 16.7 | 0.246 |
| c-A/Bx | 2.7 | 3.2 | 0.741 |
| c-B1/B1 | 0.4 | 0 | 1.000 |
| c-B1/Bx | 1.5 | 0 | 0.124 |
| c-B2/B2 | 1.2 | 0 | 0.249 |
| c-B3/B3 | 22.2 | 23 | 0.830 |
| c-B3/Bx | 0.8 | 0.4 | 1.000 |
| c-Bx/Bx | 1.2 | 0.8 | 1.000 |
| t-A/A | 59 | 57.1 | 0.670 |
| t-A/B1 | 23 | 27.4 | 0.252 |
| t-A/Bx | 14.9 | 9.5 | 0.062 |
| t-B1/B1 | 1.9 | 2.8 | 0.519 |
| t-B1/Bx | 0.4 | 2.8 | |
| t-Bx/Bx | 0.8 | 0.4 | 1.000 |
Cen: centromeric; Tel: telomeric; Cen-Bx: other Cen-B genotypes except Cen-B1, Cen-B2 and Cen-B3. Tel-Bx: other Tel-B genotypes except Tel-B1.
KIR-HLA compound genotype distribution.
| KIR-HLA | SM patients group (%) | Healthy control group (%) | P |
|---|---|---|---|
| 3DS1+Bw4/x | 25.3 | 29.9 | 0.263 |
| 3DL1+Bw4/x | 73.0 | 71.3 | 0.687 |
| 3DL1S1+Bw4/x | 74.3 | 75.7 | 0.713 |
| 3DS1+Bw4/Bw4 | 6.0 | 12.0 | |
| 3DL1+Bw4/Bw4 | 22.3 | 22.0 | 0.831 |
| 3DL1S1+Bw4/Bw4 | 22.3 | 23.9 | 0.680 |
| 2DL2+C1/x | 20.4 | 19.9 | 0.906 |
| 2DL3+C1/x | 86.7 | 90.0 | 0.258 |
| 2DL2/3+C1/x | 90.3 | 90.0 | 0.934 |
| 2DS2+C1/x | 19.5 | 18.7 | 0.837 |
| 2DL2+C1/C1 | 10.2 | 10.0 | 0.937 |
| 2DL3+C1/C1 | 46.5 | 48.6 | 0.640 |
| 2DS2+C1/C1 | 9.3 | 9.6 | 0.920 |
| 2DL1+C2/x | 50.0 | 51.0 | 0.828 |
| 2DS1+C2/x | 22.6 | 19.1 | 0.355 |
*: x represents Bw4, Bw6, C1, or C2